A new phage consortium hosts its first public lecture

Issue 55 | December 6, 2019
13 min read
Capsid and Tail

Dr. Urmi Bajpai at the IBRC lecture and panel. Please visit the IBRC Facebook page for more photos!

This week, Dr. Urmi Bajpai, a phage researcher in New Delhi, India and co-creator of the International Bacteriophage Research Consortium, tells us about a public phage therapy lecture her Consortium held last month to raise awareness of phage therapy and antibiotic resistance in India.

Also in this issue: phages working well against tomato bacteria, collateral effects of phage infection, new investment in the phage biotech company APT, Swiss researchers receive a substantial phage therapy grant, and more!

What’s New

Anushila Chatterjee (University of Colorado) and colleagues have used transposon library screening and RNA sequencing to thoroughly investigate the interaction of E. faecalis with a virulent phage. They show that phage predation can influence complex microbial behavior, which could have collateral effects on surrounding microbes during phage therapy.

ResearchPhage-host interactions

Xiaofang Wang (Nanjing Agricultural University) and colleagues have studied the efficacy of different phage combinations on Ralstonia solanacearum infection of tomato plants, and found that increasing the number of phages used at a time decreased the incidence of disease by up to 80% in greenhouse and field experiments. Nature Biotech Paper | Ars Technica article

ResearchPhage BiocontrolCrop disease

The not-for-profit healthcare organization Hackensack Meridian Health has invested in the phage biotech company Adaptive Phage Therapeutics (APT). According to APT’s CEO, Greg Merril, “The high level of interest from strategic and financial investors in support of our expanding clinical pipeline validates the potential phage therapy holds for patients.”


The Swiss National Science Foundation (SNSF) has announced its support of a phage project through a Sinergia Grant of more than CHF 3 million. This is a joint project between Prof. Martin Loessner of ETH Zurich, Prof. Jonas Marschall of Bern University Hospital, and Prof. Thomas Kessler of the Inselspital, Balgrist University Hospital, and will involve the treatment of urinary tract infections with phages.

Grant FundingPhage Therapy

Applications for the Pharmabiotics 2020 Young Investigators Awards are now open! This is a co-initiative by the Pharmabiotic Research Institute (PRI) and Institut Mérieux. An award of €10,000 will be allocated to a young clinician or academic working within the field of microbiotic medicinal products. If you have less than 15 years of clinical practice experience and serve in a hospital or research/academic institution, submit your application by January 12, 2020.


Are you attending the International Conference on Bacteriophage Research and Antimicrobial Resistance next week (Dec 12-13) in Vellore, India?

ConferencePhage Therapy

Latest Jobs

Academic PhD Project SymbiosisViral metagenomics

PhD student position: Are bee viruses driving heritable symbiont success?

Oxford Brookes University, Oxford, UK

Recently, it has been demonstrated that inherited symbionts may protect their hosts from certain pathogens. Such protective phenotypes are potentially beneficial in terms of host fitness, and thus could aid symbiont establishment. This prediction is supported through ecological modeling, but has rarely been tested in natural settings.

Solitary bees and Wolbachia bacteria will be used as model host/symbiont system. The candidate will investigate natural populations of bees and measure symbiont and viral titres in different species collected in and around Oxfordshire. These data will be used to determine if symbiont infection status predicts viral loads. Further, the candidate will characterize symbiont genomes through Nanopore and Illumina sequencing and use pool-Seq to determine which genomic features of the symbionts correlate negatively with viral presence. Further, novel viruses potentially interacting with symbionts will be described through viral metagenomics of solitary bee samples.

Academic Faculty MedicinePublic Health

Junior Group Leader Positions, Institut Pasteur

Institut Pasteur, Paris, France

Outstanding candidates are invited to apply for independent group leader positions in any of the 12 scientific departments on its campus in Paris, France.

Institut Pasteur is a non-profit private foundation dedicated to fundamental, interdisciplinary research and to the translation of knowledge for applications in medicine and public health (https://research.pasteur.fr/en/departments/). Located in central Paris, it offers an outstanding and unparalleled research environment with state-of-the-art research laboratories, and 20 technology platforms, including a core facility with four cutting-edge cryo-electron microscopes allowing single particle analysis and cellular tomography.

Successful junior candidates will be appointed with a permanent position, and as head of a group of 6 people. These groups will be created for a period of 5 years and may thereafter compete for a full research group.

Community Board

Anyone can post a message to the phage community — and it could be anything from collaboration requests, post-doc searches, sequencing help — just ask!

Seeking optimised protocol for isolation of phages from seawater samples

I am working on isolation and characterisation of marine phages for anti-bio fouling activity. Our lab has assessed the influence of chlorine on different marine microorganisms as well as barnacles, and now we are looking into use of marine bacteriophage therapy for targeting the biofilms involved in microfouling which leads to macrofouling.

I am optimising a protocol for isolation of phages from marine water samples, but somewhere I am making mistakes, leading to negative results. Could anyone please share their optimised protocol for isolation of bacteriophages from sea water samples? Until now I have used a protocol which includes dilution of filtered sea water with 2X culture broth and overnight grown pure culture, but I am looking for an alternate protocol.

Please email me at [email protected] if you can help.

Marine phagesProtocolsPhage Isolation

Seeking phage proteomics protocol

Ael Hardy

Has anyone successfully performed proteomics (LC-MS) on whole phage particles (not bands from SDS-PAGE gels)?

Looking for alternative protocols as the one I have been trying has given me a hard time. — @ael_hardy, via Twitter


Binomial nomenclature for virus species: a consultation

International Committee on Taxonomy of Viruses (ICTV)

Bas Dutilh

We are thinking about making virus taxonomy more consistent with the rest of biology by introducing binomial species nomenclature. You know: genus name & species epithet. Do you have an opinion about this? Let us know: Paper | ICTV Public Forum | Tweet thread

Viral TaxonomyNomenclature

A new phage consortium hosts its first public lecture

Profile Image
Associate Professor
International Bacteriophage Research Consortium (PI), University of Delhi, New Delhi, India

Urmi has a Ph.D. in Microbiology from University of Delhi, and is an Associate Professor, Department of Biomedical Science at Acharya Narendra Dev College (ANDC), University of Delhi.

She was the founding member of the department established in 1999 and pioneered the undergraduate research program in the college, and served as Deputy Dean of Research at the Research Council in University of Delhi (2017-2018).

She currently supervises research scholars and is Principal Investigator of several extramural funded research projects since 2006 and has established a well-equipped project laboratory in the college.

She is leading the International Bacteriophage Research Consortium (IBRC) in collaboration with Open Health System Laboratories (OHSL), USA and promoting the cause for phage therapy through her research projects, blogs and films (dubbed in several regional languages).

The event: who, what, when and where?

Last month, the International Bacteriophage Research Consortium (IBRC) held its first public phage therapy lecture to raise awareness of phage therapy and antibiotic resistance in India. The event, which was entitled the Open Health Systems Colloquium, brought together scientists, clinicians, regulatory authorities and more to discuss phage therapy and to hear perspectives from patients, their family members, researchers, regulators, funders and more.

The subject of the lecture was “The Perfect Predator: A Scientist’s Race to Save Her Husband From a Deadly Superbug” by Prof. Steffanie Strathdee, and the event also included a phage therapy panel discussion and Q&A. The event was held at the India International Centre, located in the heart of New Delhi, on November 19, 2019.

In support of WHO’s World Antibiotic Awareness Week

This programme coincided with World Antibiotic Awareness Week, which was November 18 - 24 of this year, a campaign by the World Health Organization (WHO) to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers and policymakers to avoid the further emergence and spread of antimicrobial resistance (AMR). One of the key objectives of the WHO’s Global Action Plan is to improve awareness and understanding of antimicrobial resistance.


There were about 90-100 attendees from several parts of India, who were scientists, doctors, professors, research scholars, medical students, journalists, science communicators, venture capitalists, representatives of the WHO and funding agencies such as the NIH and the Government of India’s Department of Biotechnology, and the general public.

The goal: improving awareness of phage therapy in India

The event began with a welcome note and introduction to the Open Health Systems Colloquium (OHSC) by Dr. Koninika Ray, Director, Biomedical Research, Open Health Systems Laboratory USA (OHSL). The OHSC is a collaboration between the OHSL and the India International Centre. The aim of OHSC is to open discussions into the public domain, such that the latest developments in biomedical sciences are accessible to those interested and to spark debate and deliberation across disciplines.

We were excited since this was the first public lecture organized by IBRC to create awareness on the potential of phage therapy in the country. In India, while research on various aspects of phages is going on, phage therapy is not practiced here. In the past few years, however, there is a growing curiosity about it. Hence, we were happy to hold this session and have the presence of those who have done substantial research on phage therapy and those who had first-hand experience of receiving phage therapy.

The power of a global village: Steffanie Strathdee and Tom Patterson share their phage therapy experience

The invited speaker, Prof. Steffanie Strathdee, narrated the story of her husband, Prof. Tom Patterson, Professor of Psychiatry at University of California, San Diego, who survived a pan resistant A. baumannii infection due to intervention with phage therapy. Tom’s phage therapy was made possible by a global village of researchers and healthcare workers. She mentioned how this led to IPATH, the first phage therapy centre in North America. Prof. Patterson also briefly shared his experience as a patient in coma, and told us how thankful he is to all those who came together to his rescue.

The WHO weighs in on phage therapy, AMR, and India’s progress to date

Dr. Tjandra Yoga Aditama, Director, Communicable Diseases, WHO South-East Asia Region, addressed the audience and explained the initiatives and points of action by WHO SEARO (South-East Asia Regional Office) to manage the AMR crisis. He delivered the message of the regional director, WHO Dr. Poonam Khetrapal Singh, who could attend the event due to unforeseen circumstances. Dr. Singh’s message was that the prospect of phage therapy would be of value once necessary clinical trials take place and regulatory frameworks are established. She complimented India for joining the global AMR R&D hub and said India has a lot to offer to the cause.

The International Bacteriophage Research Consortium: building multidisciplinary teams to make phage therapy possible

I gave an introduction to the IBRC and the consortium members, and presented our envisioned road map.

The IBRC was created by OHSL and Acharya Narendra Dev College, to bring together scientists, academia, clinicians, researchers and regulatory authorities to interact, share and collaborate with an aim to contribute towards phage therapy and research.

I invited the audience to join the consortium, and highlighted the need for building teams with diverse expertise to make phage therapy possible in India.

First Indian to receive phage therapy: Pranav Johri tells his story

Mr. Pranav Johri, who was the first Indian to have undertaken phage therapy (at the Eliava Institute in Tbilisi, Georgia), was invited to present his experience. He and his wife, Mrs. Apurva Johri, also shared their initiatives to facilitate Indian patient access to phage therapy in Tbilisi.

Panel discussion: Charting a path toward phage therapy


  • Prof. Steffanie Strathdee
  • Prof. Thomas Patterson
  • Dr. Biswajit Biswas, Chief of the Division of Bacteriophage Science, Biological Defense Research Directorate, Naval Medical Research Center, Fort Detrick, Maryland (joined through video conference)
  • Prof. Sanjay Chhibber, Department of Microbiology, Panjab University, President of the Society for Bacteriophage Research and Therapy (SBRT)
  • Dr. Urmi Bajpai (moderated the session)

Diverse applications for phages: vaccines, diagnostics, lysins

Dr. Biswas described his work on developing a phage bank, and mentioned phages’ application as vaccines and diagnostic agents, besides their therapeutic role, where there is a great opportunity for precision-based therapy. He said India should harvest natural phages, given their abundant presence in the natural environment. Prof. Chhibber briefly mentioned the research work being done by phage researchers in India, and shared work from his lab on nanoparticle-based delivery of endolysins and hydrogel-based phage delivery in a burn wound model.

Questions from the audience: safety, legality and ethics

A wide spectrum of queries from the audience were asked, which included legal and ethical aspects of enabling distance phage therapy, the immune system’s response to phages (how do administered phages remain in circulation without being cleared by the immune system?), criteria for their safe preparation and administration, whether phages have receptors on human cells, whether they can cross the blood brain barrier, whether resistance is developed by phages, the cost of phage therapy, and the major hurdles to get the therapy started in India. The queries were answered by Dr. Biswas and Prof. Chhibber.

Going forward: what is needed for phage therapy to become a reality in India?

  • Translational studies, clinical-grade phages, phage cocktails and clinical trials
  • Training programs to facilitate capacity building
  • Discussions on the regulatory and safety aspects of phage therapy

More resources

Check out the IBRC’s website, and if you’re a scientist working on phages, please join the consortium!

Check out the upcoming ICBRAMR conference, hosted Dec. 12-13 in Vellore, India by the Society for Bacteriophage Research and Therapy.

Capsid & Tail

Follow Capsid & Tail, the periodical that reports the latest news from the phage therapy and research community.

We send Phage Alerts to the community when doctors require phages to treat their patient’s infections. If you need phages, please email us.

Sign up for Phage Alerts

In collaboration with

Mary Ann Liebert PHAGE

Supported by

Leona M. and Harry B. Helmsley Charitable Trust

Crossref Member Badge